BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients
NCT03944356 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 232
Last updated 2025-03-12
Summary
Adjuvant therapy with dabrafenib plus trametinib in melanoma was approved in 2018 by the EMA (EUropean Medicines Agency).
The purpose of this non-interventional study is to assess the usage of adjuvant dabrafenib and trametinib in clinical practice, where the patient population may differ from study population.
Conditions
Interventions
- DRUG
-
Dabrafenib and Trametinib
Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
Sponsors & Collaborators
-
EuMelaReg gGmbH
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-07-01
- Primary Completion
- 2023-12-31
- Completion
- 2024-10-08
Countries
- Germany
Study Locations
More Related Trials
-
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
NCT01978236 ·Status: TERMINATED ·Phase: PHASE2
-
Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
NCT06557291 ·Status: COMPLETED
-
Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK
NCT03553329 ·Status: COMPLETED
-
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
NCT02039947 ·Status: COMPLETED ·Phase: PHASE2
-
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
NCT03352947 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
NCT02083354 ·Status: COMPLETED ·Phase: PHASE2
-
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
NCT02416232 ·Status: NO_LONGER_AVAILABLE
-
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
NCT01972347 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
NCT03391050 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
NCT02110355 ·Status: COMPLETED ·Phase: PHASE1
-
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
NCT05171374 ·Status: UNKNOWN
-
Radiotherapy & Combi in Metastatic Melanoma
NCT02392871 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04666272 ·Status: ACTIVE_NOT_RECRUITING
-
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
NCT01940809 ·Status: TERMINATED ·Phase: PHASE1
-
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
NCT04547946 ·Status: COMPLETED
-
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
NCT02027961 ·Status: COMPLETED ·Phase: PHASE1
-
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
NCT03272464 ·Status: TERMINATED ·Phase: PHASE1
-
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
NCT04759846 ·Status: WITHDRAWN ·Phase: PHASE1
-
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
NCT04544202 ·Status: NO_LONGER_AVAILABLE
-
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
NCT02143050 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT03543969 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
NCT05299580 ·Status: WITHDRAWN ·Phase: PHASE2
-
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
NCT04489433 ·Status: NO_LONGER_AVAILABLE
-
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
NCT04961619 ·Status: COMPLETED
-
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
NCT01878396 ·Status: UNKNOWN